ROYALTY PHARMA OA DL-0001
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, infectious disease, hematology, and diabete… Read more
Market Cap & Net Worth: ROYALTY PHARMA OA DL-0001 (RPD)
ROYALTY PHARMA OA DL-0001 (F:RPD) has a market capitalization of $17.11 Billion (€16.67 Billion) as of March 18, 2026. Listed on the F stock exchange, this Germany-based company holds position #1234 globally and #86 in its home market, demonstrating a 2.17% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ROYALTY PHARMA OA DL-0001's stock price €39.02 by its total outstanding shares 427247489 (427.25 Million).
ROYALTY PHARMA OA DL-0001 Market Cap History: 2020 to 2026
ROYALTY PHARMA OA DL-0001's market capitalization history from 2020 to 2026. Data shows growth from $15.72 Billion to $17.11 Billion (2.54% CAGR).
ROYALTY PHARMA OA DL-0001 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ROYALTY PHARMA OA DL-0001's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of RPD by Market Capitalization
Companies near ROYALTY PHARMA OA DL-0001 in the global market cap rankings as of March 18, 2026.
Key companies related to ROYALTY PHARMA OA DL-0001 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #158 globally with a market cap of $118.01 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.58 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #158 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $118.01 Billion | $466.10 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.58 Billion | $756.91 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
ROYALTY PHARMA OA DL-0001 Historical Marketcap From 2020 to 2026
Between 2020 and today, ROYALTY PHARMA OA DL-0001's market cap moved from $15.72 Billion to $ 17.11 Billion, with a yearly change of 2.54%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €17.11 Billion | +18.85% |
| 2025 | €14.40 Billion | +34.66% |
| 2024 | €10.69 Billion | +0.68% |
| 2023 | €10.62 Billion | -28.77% |
| 2022 | €14.91 Billion | +2.37% |
| 2021 | €14.56 Billion | -7.34% |
| 2020 | €15.72 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of ROYALTY PHARMA OA DL-0001 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $17.11 Billion USD |
| MoneyControl | $17.11 Billion USD |
| MarketWatch | $17.11 Billion USD |
| marketcap.company | $17.11 Billion USD |
| Reuters | $17.11 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.